Skip to main content
Premium Trial:

Request an Annual Quote

Give Us the Money

Nuvelo and Arca Biopharma announced yesterday that they will be merging to make a late-stage cardiovascular biotechnology company. Nuvelo's alfimeprase, a drug to treat blood clots, failed last year but Nuvelo retained $76 million. This is an example, says Reuters, of failed or failing biotechs being taken over for access to their excess cash. The San Jose Business Journal writes that the combined company should have enough funding until the end of 2009.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.